Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06188702
Status:
RECRUITING
Last Update Posted:
2024-05-02
First Post:
2023-12-18
Brief Title:
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase MTAP Gene
Sponsor:
Servier Bio-Innovation LLC
Organization:
Servier
Study Overview
Official Title:
A Phase 1 Open-label Multicenter Clinical Trial of S095035 MAT2A Inhibitor in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human Phase 1 multicenter open-label dose escalation study of S095035 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen and for whom additional effective standard treatment is not available S095035 is an oral methionine adenosyltransferase 2A MAT2A inhibitor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None